|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/15/19 CASI Pharmaceuticals, Inc. 10-Q 3/31/19 78:5.6M Toppan Merrill/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 239K
2: EX-4.1 Instrument Defining the Rights of Security Holders HTML 49K
3: EX-4.2 Instrument Defining the Rights of Security Holders HTML 47K
4: EX-4.3 Instrument Defining the Rights of Security Holders HTML 44K
5: EX-4.4 Instrument Defining the Rights of Security Holders HTML 44K
6: EX-10.1 Material Contract HTML 231K
7: EX-10.2 Material Contract HTML 31K
8: EX-10.3 Material Contract HTML 430K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
19: R1 Document and Entity Information HTML 45K
20: R2 Unaudited Condensed Consolidated Balance Sheets HTML 98K
21: R3 Unaudited Condensed Consolidated Balance Sheets HTML 43K
[Parenthetical]
22: R4 Unaudited Condensed Consolidated Statements of HTML 78K
Operations and Comprehensive Loss
23: R5 Unaudited Condensed Consolidated Statements of HTML 72K
Stockholders' Equity
24: R6 Condensed Consolidated Statements of Cash Flows HTML 108K
25: R7 Basis of Presentation HTML 37K
26: R8 New Accounting Pronouncements HTML 34K
27: R9 Investment in Equity Securities HTML 55K
28: R10 Inventories HTML 25K
29: R11 Leases HTML 91K
30: R12 Intangible Assets HTML 79K
31: R13 Redeemable Noncontrolling Interest HTML 40K
32: R14 Stockholders' Equity HTML 67K
33: R15 Net Loss Per Share HTML 25K
34: R16 Stock-Based Compensation HTML 126K
35: R17 Income Taxes HTML 28K
36: R18 Fair Value Measurements HTML 105K
37: R19 Related Party Transactions HTML 27K
38: R20 License Arrangements HTML 32K
39: R21 Commitments HTML 28K
40: R22 Subsequent Event HTML 28K
41: R23 New Accounting Pronouncements (Policies) HTML 31K
42: R24 Investment in Equity Securities (Tables) HTML 51K
43: R25 Leases (Tables) HTML 88K
44: R26 Intangible Assets (Tables) HTML 77K
45: R27 Redeemable Noncontrolling Interest (Tables) HTML 31K
46: R28 Stockholders' Equity (Tables) HTML 63K
47: R29 Stock-Based Compensation (Tables) HTML 121K
48: R30 Fair Value Measurements (Tables) HTML 80K
49: R31 Basis of Presentation (Details Textual) HTML 32K
50: R32 New Accounting Pronouncements (Details Textual) HTML 25K
51: R33 Investment in Equity Securities (Details) HTML 26K
52: R34 Investment in Equity Securities (Details Textual) HTML 22K
53: R35 Inventories (Details Textual) HTML 25K
54: R36 Leases (Details) HTML 26K
55: R37 Leases (Details 1) HTML 25K
56: R38 Leases (Details 2) HTML 41K
57: R39 Leases (Details 3) HTML 37K
58: R40 Leases (Details Textual) HTML 31K
59: R41 Intangible Assets (Details) HTML 33K
60: R42 Intangible Assets (Details 1) HTML 35K
61: R43 Intangible Assets (Details Textual) HTML 28K
62: R44 Redeemable Noncontrolling Interest (Details) HTML 32K
63: R45 Redeemable Noncontrolling Interest (Details HTML 45K
Textual)
64: R46 Stockholders' Equity (Details) HTML 43K
65: R47 Net Loss Per Share (Details Textual) HTML 23K
66: R48 Stock-Based Compensation (Details) HTML 28K
67: R49 Stock-Based Compensation (Details 1) HTML 32K
68: R50 Stock-Based Compensation (Details 2) HTML 53K
69: R51 Stock-Based Compensation (Details Textual) HTML 48K
70: R52 Income Taxes (Details Textual) HTML 23K
71: R53 Fair Value Measurements (Details) HTML 31K
72: R54 Fair Value Measurements (Details Textual) HTML 26K
73: R55 Related Party Transactions (Details Textual) HTML 28K
74: R56 Commitments (Details Textual) HTML 34K
75: R57 Subsequent Event (Details Textual) HTML 25K
77: XML IDEA XML File -- Filing Summary XML 126K
76: EXCEL IDEA Workbook of Financial Reports XLSX 57K
13: EX-101.INS XBRL Instance -- casi-20190331 XML 1.30M
15: EX-101.CAL XBRL Calculations -- casi-20190331_cal XML 106K
16: EX-101.DEF XBRL Definitions -- casi-20190331_def XML 400K
17: EX-101.LAB XBRL Labels -- casi-20190331_lab XML 679K
18: EX-101.PRE XBRL Presentations -- casi-20190331_pre XML 579K
14: EX-101.SCH XBRL Schema -- casi-20190331 XSD 122K
78: ZIP XBRL Zipped Folder -- 0001144204-19-026264-xbrl Zip 101K
Exhibit 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
I, Wei-Wu He, certify that:
1. I have reviewed this quarterly report on Form 10-Q of CASI Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: May 15, 2019
| /s/ Wei-Wu He | |
| Wei-Wu He | |
| Chief Executive Officer |
C:
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/15/19 | 8-K | ||
| For Period end: | 3/31/19 | NT 10-Q | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/28/24 CASI Pharmaceuticals, Inc. 20-F 12/31/23 142:21M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 4/26/23 CASI Pharmaceuticals, Inc. (DE) 20-F 12/31/22 129:16M Toppan Merrill Bridge/FA 3/28/22 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/21 104:11M Toppan Merrill Bridge/FA 3/30/21 CASI Pharmaceuticals, Inc. (DE) 10-K 12/31/20 109:13M Toppan Merrill Bridge/FA |